

J Margriet CollÃ©e

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6832517/publications.pdf>

Version: 2024-02-01

45
papers

6,422
citations

218381

26
h-index

223531

46
g-index

51
all docs

51
docs citations

51
times ranked

11278
citing authors

#	ARTICLE	IF	CITATIONS
1	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	13.7	1,099
2	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	2.6	711
3	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. <i>Nature</i> , 2014, 514, 92-97.	13.7	548
4	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015, 47, 373-380.	9.4	513
5	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493
6	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	3.8	390
7	Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics. <i>PLoS Genetics</i> , 2008, 4, e1000054.	1.5	315
8	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
9	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
10	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. <i>American Journal of Human Genetics</i> , 2013, 92, 489-503.	2.6	201
11	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978.	9.4	184
12	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	1.5	174
13	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
14	Survival after bilateral risk-reducing mastectomy in healthy <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 723-733.	1.1	111
15	Evidence that breast cancer risk at the 2q35 locus is mediated through <i>IGFBP5</i> regulation. <i>Nature Communications</i> , 2014, 5, 4999.	5.8	105
16	Common variants in <i>LSP1</i> , 2q35 and 8q24 and breast cancer risk for <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Human Molecular Genetics</i> , 2009, 18, 4442-4456.	1.4	99
17	Refined histopathological predictors of <i>BRCA1</i> and <i>BRCA2</i> mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , 2014, 16, 3419.	2.2	97
18	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88

#	ARTICLE	IF	CITATIONS
19	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012, 14, R33.	2.2	78
20	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20.	2.6	76
21	<i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2789-2799.	0.4	75
22	MicroRNA Related Polymorphisms and Breast Cancer Risk. <i>PLoS ONE</i> , 2014, 9, e109973.	1.1	49
23	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
24	Endometrial Cancer Risk in Women With Germline <i>BRCA1</i> or <i>BRCA2</i> Mutations: Multicenter Cohort Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1203-1211.	3.0	44
25	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 837-848.	2.6	39
26	Ovarian cancer susceptibility alleles and risk of ovarian cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Human Mutation</i> , 2012, 33, 690-702.	1.1	34
27	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i> / <i>BRCA2</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	3.0	30
28	RAD51B in Familial Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0153788.	1.1	26
29	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	1.1	22
30	Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers. <i>British Journal of Cancer</i> , 2018, 119, 357-363.	2.9	22
31	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	2.9	19
32	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	5.8	19
33	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. <i>Genome Medicine</i> , 2022, 14, 51.	3.6	19
34	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18
35	The development of an online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive decision-making: a usability and pilot study. <i>Familial Cancer</i> , 2019, 18, 137-146.	0.9	17
36	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	1.1	16

#	ARTICLE	IF	CITATIONS
37	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	2.2	15
38	Online decision support for persons having a genetic predisposition to cancer and their partners during reproductive decision-making. <i>Journal of Genetic Counseling</i> , 2019, 28, 533-542.	0.9	14
39	Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female <i>BRC</i> A Mutation Carriers in the Netherlands. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2482-2491.	1.1	11
40	Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). <i>JMIR Research Protocols</i> , 2021, 10, e24414.	0.5	9
41	Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-making. <i>Journal of Community Genetics</i> , 2021, 12, 101-110.	0.5	6
42	Rare germline copy number variants (CNVs) and breast cancer risk. <i>Communications Biology</i> , 2022, 5, 65.	2.0	6
43	Recurrent <i>HOXB13</i> mutations in the Dutch population do not associate with increased breast cancer risk. <i>Scientific Reports</i> , 2016, 6, 30026.	1.6	3
44	rs2735383, located at a microRNA binding site in the 3'UTR of <i>NBS1</i> , is not associated with breast cancer risk. <i>Scientific Reports</i> , 2016, 6, 36874.	1.6	2
45	Germline <i>HOXB13</i> mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020, 10, 9688.	1.6	2